Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference

About this update from Sensorion Sas

[{"type":"text","content":"MONTPELLIER, France, December 19, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced today that it will participate in the 44th Annual J.P. Morgan Healthcare Conference, San Francisco, USA, to be held on January 12-15, 2026.","length":362,"tagName":"p"},{"type":"text","content":"Nawal Ouzren, Chief Executive Officer of Sensorion, will make a presentation on January 15, 2026, at 08:15am PT (05:15pm CET). A Q&A session will follow the presentation.","length":174,"tagName":"p"},{"type":"text","content":"About SensorionSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.","length":462,"tagName":"p"},{"type":"text","content":"It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.","length":629,"tagName":"p"},{"type":"text","content":"Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion’s small molecule progressed in three Phase 2 proof of concept clinical study: firstly, in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing, for which the recruitment is completed, and the ...

More updates from Sensorion Sas